Gene Editing · us
Letting a Backup Protein Take Over: CRISPR Improves Muscle Function in Mice with Duchenne Muscular Dystrophy
A University of Pennsylvania team is trying to increase production of utrophin to compensate for the function of missing dystrophin in muscle. Mouse experiments showed signs of improved muscle strength and fewer abnormal muscle fibers, but demonstrating efficacy in humans remains some way off.
Every muscle contraction relies on proteins to maintain structural stability. In people with Duchenne muscular dystrophy, genetic mutations impair this protective mechanism. A University of Pennsylvania research team has now tried increasing the supply of another protein to take over some of that work, observing improved muscle function in mouse models.
Penn Medicine announced on October 26 that the team used CRISPR to edit the utrophin gene, increasing production of the protein. Rather than directly repairing the disease-causing DMD gene, the research aims to mobilize an existing alternative mechanism in muscle to compensate for the functional gap left by the loss of dystrophin.
Insufficient dystrophin leaves muscles vulnerable to ongoing damage during everyday activities, causing them to weaken gradually. Utrophin has the potential to perform some similar functions, but the key question is whether enough can be produced. This makes increasing production of the backup protein the central focus of the research.
To deliver the editing tools into cells, the team explored muscle-targeting MyoAAV viral vectors and the delivery of mRNA using lipid nanoparticles. The latter draws on a technological concept associated with some COVID-19 vaccines, enabling cells to temporarily produce the tools needed for gene editing. The effectiveness and limitations of both delivery methods still require further clarification.
Treated mice showed improved muscle strength and reductions in some disease-related abnormalities in muscle fibers. However, the study was originally designed primarily to test whether disease progression could be prevented. These results are not yet sufficient to establish that already damaged muscles can fully recover, nor can they be used to infer directly that patients would receive the same benefits.
The currently available press release does not report sample sizes, the magnitude of improvement, or long-term safety data, and benefits in humans have yet to be verified. The team is continuing to investigate more precise and efficient editing tools and other delivery methods. The next test for this work is whether the signs of functional improvement in mice can translate into sufficiently durable and safe therapeutic effects in humans.